參考價	￥ 1211

信號通路

MedChemExpress (M

CAS	218137-86-1	純度	99.91%
分子量	254.32	分子式	C??H??O?
供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL
貨號	HY-12364	應用領域	醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥/生物制藥

C75 是合成的脂肪酸合成酶 (FASN) 抑制劑。C75 抑制前列腺癌細胞 PC3 的 IC50 值為 35 μM。C75 是有效的 CPT1A 激活劑。

詳細介紹

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。

C75

CAS No. : 218137-86-1

MCE 國際站：C75

產(chǎn)品活性：C75 是合成的脂肪酸合成酶 (FASN) 抑制劑。C75 抑制前列腺癌細胞 PC3 的 IC₅₀ 值為 35 μM。C75 是有效的 CPT1A 激活劑。

研究領域：Metabolic Enzyme/Protease

作用靶點：Fatty Acid Synthase (FASN)

In Vitro: C75 inhibits PC3 cell growht with an IC₅₀ of 35 μM at 24 h. C75 (10-50 μM) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC₅₀ of 50 μM. (-)-C75 inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity.

In Vivo: C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10–24 h after i.p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥95% within 2 h after i.p. injection. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA.